Delivery Order SPE2DB24D1201-SPE2DB25FJDZM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Naloxone 0.4 mg/ml vials, with a contract ceiling value of $2,310.50. This firm fixed-price delivery order, awarded on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a competitive award with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child...
- The Defense Logistics Agency awarded a $1,018.53 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Naloxone 0.4 mg/mL vials. This competitively awarded, firm fixed-price contract is classified as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,142.07 to AmerisourceBergen Drug Corp for the supply of Naloxone 2 mg/2 mL syringes on August 7, 2025, with an ultimate completion date of August 8, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,124.16 to AmerisourceBergen Drug Corp for Naloxone HCL 4 mg nasal spray (2-count units) on August 22, 2025, with completion scheduled for August 25, 2025. This firm fixed price contract was awarded competitively with no set-aside designation and is being performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,169.75 to AmerisourceBergen Drug Corp for the supply of Naloxone 2 mg/2 ml syringes on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Naloxone 0.4 mg/mL vials with a ceiling value of $1,444.42. This is a firm fixed-price delivery order with an ultimate completion date of August 4, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The contract contains no...
- The Defense Logistics Agency awarded a delivery order valued at $1,519.77 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 18, 2025, with completion targeted for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a single delivery order under AmerisourceBergen's larger pharmaceutical supply framework. Performance will be executed from the company's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order valued at $1,120.08 to AmerisourceBergen Drug Corp for the supply of Naloxone 2 mg/2 ml syringes on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical pharmaceutical...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the delivery of 4564091534 - NALOXONE .4MG/10ML 10S, a critical pharmaceutical product, through March 27, 2024. The contract has a ceiling value of $1,211.14 and does not have a set-aside designation. AmerisourceBergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,928.40 to AmerisourceBergen Drug Corp for Naloxone HCl 4 mg nasal spray (2-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price, non-set-aside contract is classified as a child award, indicating it derives from a larger contract vehicle. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJDZMDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,258.67 to AmerisourceBergen Drug Corp for the supply of Naloxone 0.4 mg/mL vials. The contract is structured as a firm fixed price delivery order with an ultimate completion date of August 28, 2025, and was competitively awarded without set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location and deliver the pharmaceutical product to support federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to military healthcare programs and other federal health systems worldwide. Naloxone, an opioid antagonist medication, aligns with the critical pharmaceutical commodities the company routinely provides through this contract vehicle to support Defense Health Agency, U.S. Coast Guard, and other government healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 8/27/25 |